October 25, 2017October 25, 2017

Global Blood Therapeutics Scraps Its Effort to Develop GBT440 as a Treatment for IPF

Disappointing clinical trial results have prompted Global Blood Therapeutics to scrap its program to develop GBT440 as a treatment for idiopathic pulmonary fibrosis. GBT440 increased patients’ lung oxygen levels, but not enough ... Read more

June 23, 2016June 23, 2016

Phase 2 Study of Hemoglobin Modifier, GBT440, to Treat IPF Getting Underway

Idiopathic Pulmonary Fibrosis, News

Global Blood Therapeutics (GBT) is starting a Phase 2a clinical trial to assess the company’s lead product, GBT440, as a treatment for adults with idiopathic pulmonary fibrosis (IPF) and hypoxemia. GBT440 is ... Read more